Status:
COMPLETED
Special Survey Long-term Treatment With Tiotropium on COPD
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
20+ years
Brief Summary
Since Spiriva Inhalation Capsules 18mcg (hereinafter this product) are indicated for treatment of patients with chronic obstructive pulmonary disease (i.e. patients with chronic bronchitis or pulmonar...
Eligibility Criteria
Inclusion
- Patients of Chronic Obstructive Pulmonary Disease
- Patients were expected to use the product for long period of time
Exclusion
- Patients with glaucoma
- Patients with micturition disorder due to prostatic hyperplasia etc.
- Patients with a history of hypersensitivity to atropine or its derivatives or to any component of this product
Key Trial Info
Start Date :
April 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
385 Patients enrolled
Trial Details
Trial ID
NCT00638183
Start Date
April 1 2005
Last Update
June 19 2014
Active Locations (89)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Asahikawa, Japan
2
Boehringer Ingelheim Investigational Site
Chikushino-shi, Japan
3
Boehringer Ingelheim Investigational Site
Daitō, Japan
4
Boehringer Ingelheim Investigational Site
Ebina, Japan